62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. (January 2017) - Yip, K.; Conibear, J.; Woolf, D.; Tarver, K.; Willis, B.; Hall, S.; Sun, F.; Kuhan, H.; Lambourne, B.; Piskilidis, P.; Kussaibati, R.; Martin, L.; et al.